These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16148437)

  • 1. A role for cannabinoid CB1 receptors in mood and anxiety disorders.
    Witkin JM; Tzavara ET; Nomikos GG
    Behav Pharmacol; 2005 Sep; 16(5-6):315-31. PubMed ID: 16148437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
    Moreira FA; Grieb M; Lutz B
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Functional role of the endocannabinoid system in emotional homeostasis].
    Marco EM; Viveros MP
    Rev Neurol; 2009 Jan 1-15; 48(1):20-6. PubMed ID: 19145562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice.
    Balerio GN; Aso E; Maldonado R
    Psychopharmacology (Berl); 2006 Mar; 184(3-4):504-13. PubMed ID: 16416159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
    Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.
    Vlachou S; Nomikos GG; Panagis G
    Psychopharmacology (Berl); 2006 Oct; 188(3):293-305. PubMed ID: 16953388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
    Fride E
    Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid receptors.
    Moreno M; Escuredo L; Muñoz R; Rodriguez de Fonseca F; Navarro M
    Behav Pharmacol; 2005 Sep; 16(5-6):423-30. PubMed ID: 16148447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoid system and fear conditioning.
    Resstel LB; Moreira FA; Guimarães FS
    Vitam Horm; 2009; 81():421-40. PubMed ID: 19647121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.
    Rubino T; Guidali C; Vigano D; Realini N; Valenti M; Massi P; Parolaro D
    Neuropharmacology; 2008 Jan; 54(1):151-60. PubMed ID: 17692344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect.
    McLaughlin RJ; Hill MN; Morrish AC; Gorzalka BB
    Behav Pharmacol; 2007 Sep; 18(5-6):431-8. PubMed ID: 17762511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
    Di Marzo V
    Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system.
    Perra S; Pillolla G; Luchicchi A; Pistis M
    Alcohol Clin Exp Res; 2008 Mar; 32(3):443-9. PubMed ID: 18215217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice.
    Rodgers RJ; Evans PM; Murphy A
    Behav Pharmacol; 2005 Sep; 16(5-6):405-13. PubMed ID: 16148445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.
    Bermúdez-Siva FJ; Serrano A; Diaz-Molina FJ; Sánchez Vera I; Juan-Pico P; Nadal A; Fuentes E; Rodríguez de Fonseca F
    Eur J Pharmacol; 2006 Feb; 531(1-3):282-4. PubMed ID: 16423347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CB1 receptors in psychostimulant addiction.
    Wiskerke J; Pattij T; Schoffelmeer AN; De Vries TJ
    Addict Biol; 2008 Jun; 13(2):225-38. PubMed ID: 18482432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
    Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
    Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
    Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.